Related references
Note: Only part of the references are listed.AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
Jing Yang et al.
BLOOD (2007)
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
Robert W. Wilkinson et al.
CLINICAL CANCER RESEARCH (2007)
MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy
Kara Hoar et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase
Andrew A. Mortlock et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
Mark G. Manfredi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells
Steven L. Warner et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function
Farid Gizatullin et al.
CANCER RESEARCH (2006)
TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme
Jos M. A. Kuijlen et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac et al.
BRITISH JOURNAL OF CANCER (2005)
RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells
T Hata et al.
CANCER RESEARCH (2005)
Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo
S Shankar et al.
PROSTATE (2005)
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
EA Harrington et al.
NATURE MEDICINE (2004)
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis
JE Chipuk et al.
SCIENCE (2004)
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL
R Ravi et al.
CANCER RESEARCH (2004)
Development of a tightly regulated U6 promoter for shRNA expression
XY Lin et al.
FEBS LETTERS (2004)
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway
T Ohtsuka et al.
ONCOGENE (2003)
Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
H LeBlanc et al.
NATURE MEDICINE (2002)
Minireview: The OPG/RANKL/RANK system
S Khosla
ENDOCRINOLOGY (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release
TA Röhn et al.
ONCOGENE (2001)
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
A Chuntharapai et al.
JOURNAL OF IMMUNOLOGY (2001)
p53-Independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ
RD Meng et al.
EXPERIMENTAL CELL RESEARCH (2001)
Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene, Aie1
HM Hu et al.
DNA AND CELL BIOLOGY (2000)
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
AM Chinnaiyan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
